Feb 14 |
Erasca Announces Two Clinical Trial Collaboration and Supply Agreements for Trametinib to Evaluate Naporafenib Combination in SEACRAFT-1 and SEACRAFT-2 Trials
|
Feb 1 |
Erasca to Present at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
|
Jan 9 |
Is Erasca (NASDAQ:ERAS) In A Good Position To Invest In Growth?
|
Jan 3 |
Erasca to Present at the 42nd Annual J.P. Morgan Healthcare Conference
|
Dec 20 |
3 Penny Stocks You’ll Regret Not Buying Soon: December Edition
|
Dec 13 |
Erasca Co-Founder Acquires 3.2% More Stock
|
Dec 11 |
RiskOn International And 3 Other Stocks Under $2 Insiders Are Buying
|
Dec 11 |
Erasca Granted FDA Fast Track Designation for Pan-RAF Inhibitor Naporafenib in Patients with Advanced NRAS-Mutated Melanoma
|
Dec 7 |
Erasca CEO Lim buys stock worth $1.7M - filing
|
Dec 7 |
Erasca director Alexander Casdin discloses purchase of 30K shares
|